Omnigen DFU Pilot Study

University Hospitals of Derby and Burton NHS Foundation Trust

Status

Completed

Conditions

Diabetic Foot Ulcers

Treatments

Other: Dummy Packaging

Other: Omnigen

Study type

Interventional

Funder types

Other

Identifiers

NCT03483467

DHRD/2017/042

Details and patient eligibility

About

The Omnigen Pilot study aims to provide an evidence base for Omnigen as a treatment for Diabetic Foot Ulcers (DFU). It aims to achieve this by tailoring a regenerative therapy used for ocular surface repair to provide proactive non-surgical wound management of Diabetic Foot Ulcers (DFU).

Full description

This pilot study is designed as a multi-centre prospective, patient and observer blind, randomised controlled trial, recruiting patients from two clinical centres across the East Midlands; Derby Teaching Hospitals NHS Foundation Trust (DHFT) and Nottingham University Hospitals NHS Trust (NUH).

Eligible patients will be approached within diabetic foot clinics by their usual clinical carers to determine whether they are interested in participating in the study. They will be provided with written information about the study and the researcher will explain the study verbally to them and address any questions and concerns the patient may have. Patents will be given at least 24 hours to consider taking part in the trial before signing a consent form.

After informed consent has been given, baseline information will be collected. This will include demographic information, medical history and concomitant medication. eGFR and HbA1c will also be collected if not done within previous 3 months as part of standard care. The baseline wound status, assessment of ulcer infection according to Infectious Diseases Society of America (IDSA) criteria, peripheral pulses, neuropathy and ankle brachial pressure index will also be taken.

Participants will then be randomised to receive either standard of care or Omnigen graft with standard of care. Staff administering the Omnigen product will be aware of which treatment the participant is receiving however the participant and the research staff conducting the healing assessments will be blinded to their treatment allocation. Therefore the participant and the assessors will be blinded to the treatment given in order to minimize any bias in the collection of healing outcome data. For those randomized into the control arm, 'Dummy Packaging' will be used to ensure the blind is maintained.

Patients will be seen two weekly from their baseline visit until healing for up to 12 weeks and at 2 weeks post healing in those that heal. If a participant's foot ulcer heals before the final 12 weeks visit, they will attend a healing confirmation visit two weeks post the original heal date, however will not be required to attend any further fortnightly visits until the final blinded assessment visit at week 12 . If the participant's foot ulcer has not healed at 12 weeks then a blinded assessment should still be conducted at this time point.

Data is collected using the Dacima Clinical Suite Electronic Data Capture (EDC) software (Dacima Software Inc.)

Enrollment

31 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients with diabetes (according to WHO criteria) aged 18 years or over
At least one full thickness ulcer below the malleolus of either foot, present for 4 weeks or more.
At least one palpable pulse on the foot of the index limb or an ABPI >0.9
Minimum ulcer diameter of 5 mm
Maximum ulcer diameter of 20 mm.
Able to attend clinic on a fortnightly basis

Exclusion criteria

eGFR <20
HbA1c >108
Planned revascularisation during the course of the study or within the 4 weeks preceding the start of the study
An ulcer of aetiology other than diabetes
Depth of ulcer to bone, suspected or confirmed osteomyelitis
Severe infection of the index ulcer
Active Charcot of the foot of the index ulcer
The need for negative pressure wound therapy
On treatment with systemic steroids at a dose > equivalent of 5mg prednisolone for more than 5 days and/or systemic cytotoxic agents
Unwilling or unable to attend all trial visits.
Unwilling or unable to give written informed consent.
Lacks the mental capacity to give consent
Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, may influence the result of the trial or the participant's ability to participate in the trial
Participants who have participated in another research trial involving a wound healing product within the past 12 weeks